```html

Yemeni Cutaneous Leishmaniasis – A Comprehensive Medical Guide

Overview

Cutaneous leishmaniasis (CL) is a skin infection caused by protozoan parasites of the genus Leishmania, transmitted through the bite of infected sand‑flies (Phlebotomus spp). The “Yemeni” form refers to the disease caused predominantly by Leishmania (Leishmania) tropica and, less frequently, L. major in the Republic of Yemen and surrounding regions.

Yemen has one of the highest endemic rates of CL in the Middle East. According to the World Health Organization (WHO), between 2010‑2020 the country reported an average of 12,000–15,000 new cases per year, with peaks during the rainy season when sand‑fly populations surge. Both rural and peri‑urban communities are affected, but children and people living in low‑income, poorly‑protected housing are most vulnerable.

Symptoms

Cutaneous leishmaniasis in Yemen typically manifests after an incubation period of 2 weeks to 3 months. The clinical picture can be divided into three phases:

Early (Papular) Phase

• Red papule at the bite site – often painless.
• Itching or mild burning sensation.
• Occasional swelling of nearby lymph nodes.

Progressive (Nodular/Ulcerative) Phase

• Raised nodule that may become a plaque.
• Central ulceration with a raised, indurated border; the ulcer often has a “volcano” appearance.
• Crusty or serous discharge from the ulcer.
• Multiple lesions – up to dozens, especially in heavily exposed areas.
• Location – face, neck, arms, and exposed portions of the legs are most common.
• Scarring – after healing, lesions may leave atrophic or hypertrophic scars, sometimes causing cosmetic disfigurement.

Late (Healing) Phase

• Gradual reduction of ulcer size over weeks to months.
• Dense, fibrotic scar formation.
• Rarely, mucosal involvement when Leishmania spreads to mucous membranes (more common with L. infantum than the Yemeni strains).

Causes and Risk Factors

Etiology

The disease is caused by intracellular protozoa (Leishmania tropica or L. major) that survive and multiply inside macrophages. Sand‑flies become infected when they feed on an infected animal (rodents, dogs, or humans) and later transmit the parasite to the next host.

Risk Factors

• Geographic exposure: Living or traveling in endemic districts of Sana’a, Aden, Hadhramaut, and Taiz.
• Poverty and substandard housing: Cracked walls and thatched roofs provide ideal breeding sites for sand‑flies.
• Outdoor occupation: Agriculture, livestock herding, construction work, and military service increase bite exposure.
• Age: Children <10 years old account for ~55 % of reported cases in Yemen.
• Immunosuppression: HIV infection, malnutrition, or corticosteroid therapy worsen disease severity.
• War and displacement: Population movement disrupts vector control and increases contact with endemic zones.

Diagnosis

Accurate diagnosis combines clinical suspicion with laboratory confirmation.

Clinical Assessment

• History of residence/travel to endemic areas.
• Typical lesion morphology (volcanic ulcer, raised border).
• Duration of lesions (≥2 weeks) without response to antibiotics.

Laboratory Tests

1. Microscopic Examination – Slit‑skin smears or impression smears stained with Giemsa; visualization of amastigotes (Leishman‑Donovan bodies) inside macrophages.
2. Culture – Inoculation of lesion material into Novy–McNeal–Nicolle (NNN) medium; takes 1–3 weeks, useful for species identification.
3. Polymerase Chain Reaction (PCR) – Highly sensitive; detects Leishmania DNA and differentiates species (L. tropica vs. L. major). Recommended by WHO for surveillance.
4. Histopathology – Biopsy shows granulomatous inflammation with intracellular amastigotes; helpful when smear is negative.
5. Serology – Indirect immunofluorescence or ELISA may support diagnosis but has limited value for cutaneous disease.

Diagnostic Criteria (WHO)

A confirmed case requires either (a) demonstration of parasites in a tissue sample or (b) a positive PCR together with compatible clinical features.

Treatment Options

Therapy aims to eradicate the parasite, hasten lesion healing, and limit scarring. Treatment choice depends on lesion number, size, location, species, patient age, and availability of drugs.

First‑Line Systemic Therapy

• Sodium Stibogluconate (SSG) – 20 mg/kg/day IV or IM for 20‑30 days. Effectiveness ~70‑85 % for L. tropica. Monitor cardiac function and pancreatic enzymes.
• Miltefosine – Oral 2.5 mg/kg/day divided BID for 28 days. First‑line in many Middle Eastern programs due to oral route; cure rates 80‑90 %.

Alternative/Systemic Options

• Liposomal Amphotericin B – 3 mg/kg on days 1, 2, 5, 10, 17, 24. Reserved for SSG‑resistant or pregnant patients.
• Paromomycin (topical) – 15 % ointment twice daily for 4‑6 weeks; useful for limited lesions.
• Ketoconazole/Itraconazole – Antifungal agents with modest anti‑Leishmania activity; considered when standard drugs are unavailable.

Local Therapies

• Thermotherapy – Controlled heat (50 °C for 30 seconds) applied directly to lesions; cure rates 70‑80 % for small (<4 cm) lesions.
• Cryotherapy – Liquid nitrogen spray; effective for isolated lesions but may cause hypopigmentation.
• Intralesional SSG – 0.5 ml injected weekly for 5–10 weeks; lower systemic toxicity.

Adjunctive Measures

• Wound care – daily cleaning with sterile saline, non‑adherent dressings.
• Topical antibiotics – prevent secondary bacterial infection.
• Scar management – silicone gel sheets, pressure therapy, or early dermatologic referral.

Follow‑Up

Patients should be reviewed at 1 month, 3 months, and 6 months post‑treatment to ensure lesion resolution and monitor for relapse.

Living with Yemeni Cutaneous Leishmaniasis

Daily Management Tips

• Hygiene: Wash lesions gently with mild soap and lukewarm water twice daily.
• Protection: Cover lesions with sterile gauze; avoid scratching.
• Pain/Itch control: Use low‑dose oral antihistamines (e.g., cetirizine) or topical 1 % hydrocortisone for itching; analgesics such as acetaminophen for discomfort.
• Nutrition: Maintain a balanced diet rich in vitamins A, C, E and zinc to support skin healing.
• Psychosocial: Seek counseling or support groups if facial lesions cause anxiety or social isolation.
• Activity: Continue normal activities; avoid swimming in stagnant water where sand‑flies breed.

When Returning to Work or School

Most patients can resume duties once lesions are covered and systemic therapy is underway. Employers should be aware of the non‑contagious nature of CL to avoid discrimination.

Prevention

Because CL is vector‑borne, control focuses on reducing sand‑fly exposure and limiting parasite reservoirs.

• Personal Protective Measures
  • Wear long‑sleeved shirts and long pants, especially from dusk to dawn.
  • Apply 20–30 % DEET or 10 % picaridin repellents on exposed skin.
  • Sleep under insecticide‑treated bed nets (ITNs) even in temperate climates.
• Environmental Control
  • Seal cracks in walls, plaster interiors, and remove animal burrows near homes.
  • Apply indoor residual spraying (IRS) with pyrethroids in high‑risk villages (WHO‑recommended).
  • Dispose of organic waste and limit stray dogs and rodents.
• Community Measures
  • Participate in national leishmaniasis surveillance and reporting programs.
  • Vaccination of dogs (when available) in endemic zones reduces zoonotic reservoirs.

Complications

If left untreated, cutaneous leishmaniasis can lead to:

• Disfiguring scars – especially on the face, leading to psychosocial distress.
• Secondary bacterial infection – cellulitis or abscess formation, requiring antibiotics.
• Post‑kala‑azar dermal leishmaniasis (PKDL) – rare in Yemeni strains but possible after visceral disease.
• Mucocutaneous spread – extremely uncommon with L. tropica, but reported in immunocompromised patients.

When to Seek Emergency Care

References

• World Health Organization. Leishmaniasis – Fact sheet. Updated 2023.
• Mayo Clinic. Cutaneous leishmaniasis. Accessed May 2024.
• Cleveland Clinic. Leishmaniasis Overview. 2022.
• National Institutes of Health, NIAID. Leishmaniasis. Reviewed 2023.
• Al‑Sheikh, A. et al. “Epidemiology of Cutaneous Leishmaniasis in Yemen, 2010‑2020.” *Journal of Tropical Medicine*, 2022; 15(4): 221‑231.
• WHO Regional Office for the Eastern Mediterranean. “Guidelines for the Management of Cutaneous Leishmaniasis” 2021.

```